Clinical trials: Diarrhoea, open to volunteers
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)
- Trial name
- NCT06753890
- Testing
- Changkang granules
- Where
- 30 sites in China
- Volunteers
- 520 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea
Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.
- Trial name
- NCT06839209
- Testing
- Toxclean 1g
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- ABResearch S.r.l.
Diarrhoea
Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
The current study is a follow-up to 2 previous parent studies, a dose-selection study with 3 different dose-levels of the altSonflex1-2-3 vaccine in a schedule of 3 vaccinations (H06_01TP study [NCT05073003, 212149]) and a study…
- Trial name
- H06_04TP (NCT07320716)
- Testing
- AltSonflex1-2-3, Menveo, Infanrix hexa
- Where
- Kenya
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infantile Colics, Constipation
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete
This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional…
- Conditions
- Infantile Colics, Constipation, Infantile Diarrhea, Atopic Dermatitis
- Trial name
- NCT07444008
- Testing
- BioAmicus Complete
- Where
- Russia
- Volunteers
- 140 people
- Sponsor
- NovoNatum Ltd
Crohns Disease
Treatment of Moderate to Severe Refractory Crohn's Disease
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD).
- Trial name
- NCT06721962
- Testing
- TRX103, Cyclophosphamide
- Where
- 13 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Breast Cancer, Chemotherapy-induced Diarrhea
Probiotics for Abemaciclib-Induced Abdominal Discomfort.
This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment.
- Trial name
- NCT07605728
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Leeuwenhoek Laboratories Co. Ltd.
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Diarrhea
A Post-marketing Observational Study of Oral Cholera Vaccine
Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher…
- Trial name
- NCT07300462
- Testing
- Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Shanghai United Cell Biotechnology Co., Ltd
Irritable Bowel Syndrome
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
- Trial name
- NCT04880876
- Testing
- 25mg Eluxadoline, 100mg Eluxadoline
- Where
- 6 sites in United States
- Volunteers
- 124 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome, Diarrhea
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).
- Trial name
- RENEW-IBS-D (NCT07545759)
- Testing
- LY3537031
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Cryptosporidiosis
A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants
This study aims to characterize the pediatric cryptosporidiosis disease profile with respect to clinical presentation.
- Trial name
- NCT07716410
- Where
- 4 sites in Kenya, Malaysia and 1 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Health
Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions
US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms.
- Trial name
- NCT05465629
- Testing
- VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Diarrhea, Gastroenteritis
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria.
- Conditions
- Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
- Trial name
- NCT07285785
- Testing
- Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Shigella, Diarrhea
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
- Trial name
- NCT07205926
- Testing
- IVT Shigella-04
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Travelers Diarrhea
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
The goal of this interventional study is to learn about the intraluminal pharmacokinetics (PK) of the investigational drug LMN-401 in adult healthy volunteers with ileostomies.
- Trial name
- NCT06556940
- Testing
- LMN-401
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Patients With Irritable Bowel Syndrome With Diarrhea
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase II clinical trial. Its purpose is to evaluate the efficacy and safety of Huanghou Zhixie Diwan in subjects with irritable bowel…
- Trial name
- NCT07721012
- Testing
- Huanghou Zhixie Diwan group, Huanghou Zhixie Diwan mimic
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Lei Yunshang Group